{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:43:09Z","timestamp":1773236589272,"version":"3.50.1"},"reference-count":5,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecol Obstet Invest"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; It is hypothesized that the HER-2\/neu receptor could be used for targeted therapy in recurrent endometrial cancer. &lt;i&gt;Cases:&lt;\/i&gt; A patient with type II endometrial cancer (serous), showing strong HER-2\/neu overexpression and gene amplification in both primary and recurrent tumor, received single-agent trastuzumab (3\u00d7 weekly, 8 mg\/kg loading, 6 mg\/kg maintenance dose). Because of progression after 4 cycles, weekly paclitaxel-trastuzumab (80 mg\/m&lt;sup&gt;2&lt;\/sup&gt; paclitaxel; trastuzumab 4 mg\/kg loading, 2 mg\/kg maintenance dose) was initiated. However, progressive disease was also noted after 11 weeks of combined treatment. A second patient, with recurrent type II endometrial cancer (grade III endometrioid), had HER-2\/neu gene amplification in the primary tumor. However, biopsy from a lung metastasis 3 years later appeared to be HER-2\/neu-negative. &lt;i&gt;Conclusion:&lt;\/i&gt; Based on lack of response and changes in tumor biology, trastuzumab was of little clinical value in 2 cases of recurrent type II endometrial cancer. This report underscores the importance of reassessment of a recurrent tumor before initiating targeted treatment.<\/jats:p>","DOI":"10.1159\/000161568","type":"journal-article","created":{"date-parts":[[2008,10,11]],"date-time":"2008-10-11T20:33:17Z","timestamp":1223757197000},"page":"46-48","source":"Crossref","is-referenced-by-count":6,"title":["Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer"],"prefix":"10.1159","volume":"67","author":[{"given":"I.","family":"Vandenput","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vanden Bempt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Leunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Moerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Amant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2805%2967063-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2559.2005.02112.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-1438.2007.00946.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-1438.2006.00664.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-1438.2006.00543.x"}],"container-title":["Gynecologic and Obstetric Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/161568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/161568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:56:02Z","timestamp":1745456162000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000161568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,9]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000161568","archive":["Portico"],"relation":{},"ISSN":["0378-7346","1423-002X"],"issn-type":[{"value":"0378-7346","type":"print"},{"value":"1423-002X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,9]]}}}